Clinical trials: Pharyngeal Neoplasm
Aspiration, Laryngeal Cancer
NewBreez for Airway Protection in Head and Neck Cancer Patients With Chronic Aspiration
Laryngeal dysfunction is a problem that affects many patients after laryngeal cancer therapy (surgery or radio/chemotherapy). Laryngeal dysfunction is associated with higher incidences of aspiration and respiratory tract…
- Trial name
- NCT02437513
- Testing
- NewBreez
- Volunteers
- 2 people
- Sponsor
- ProTiP Medical
Adenocarcinoma (NOS), Anal Cancer
DESTINY-PANTUMOUR04
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease…
- Conditions
- Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- DP-04 (NCT07124000)
- Testing
- Trastuzumab deruxtecan
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 42 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Nasopharyngeal Neoplasms
Taxotere + Cisplatin in Nasopharyngeal Carcinoma
Primary objective: To assess and compare the toxicities of patients with advanced NPC treated with concurrent cisplatin-radiotherapy with or without neoadjuvant Taxotere (docetaxel) and cisplatin.
- Trial name
- NCT00436293
- Testing
- Docetaxel, Cisplatin
- Where
- Hong Kong
- Volunteers
- 61 people
- Sponsor
- Sanofi
Nasopharyngeal Carcinoma
SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
This is an open label, phase Ib Study of SHR-1701 in patients with recurrent/metastatic nasopharyngeal carcinoma(R/M NPC).
- Trial name
- NCT04282070
- Testing
- SHR-1701, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 91 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.